Science: Scientists have found a mechanism for drug resistance in breast cancer March 27, 2017 -- The recurrence rate of breast cancer after treatment is high, which makes many doctors and researchers worry. For example, the researchers have just found a PI3K signaling pathway associated with multiple breast cancers and designed the drug as a target, but the results of the experiment show that cancer patients will use another cancer after receiving this therapy. A signaling pathway proliferates, resulting in a higher recurrence rate. However, how cancer cells turn to another signaling pathway (ie, the estrogen receptor signaling pathway) is still a mystery. Researchers from the Memorial Sloan Catherine Medical Research Center recently published an article in the journal Science that they found the key: inhibition of PI3K signaling activates the estrogen receptor signaling pathway through epigenetic mechanisms. The key protein is called KMT2D. Epigenetics is currently a hot area in cancer research. Although epigenetic changes have important implications for lymphoma, leukemia, and other cancer types. This is the first time that epigenetic regulation has been discovered in breast cancer. "We have always known that breast cancer is a very stubborn cancer. Once one of the signaling pathways is suppressed, it will initiate other signaling pathways to proliferate. "The author of the article, Dr. José Baselga, said: "We now know two interacting signaling pathways. The discovery of this epigenetic mechanism will help us understand the function of cancer cells." The discovery of the mechanism by which KMT2D regulates the estrogen receptor signaling pathway is important for understanding the pathogenesis of breast cancer. Currently, 70% of breast cancers are dependent on estrogen receptors for proliferation. Among these estrogen receptor-positive tumors, 40% have mutations in the PI3K3CA gene, which encode a part of the PI3K protein and regulate PI3K activation. . Although the simultaneous blocking of these two signaling pathways has shown great clinical results, there are currently drugs undergoing clinical phase III trials. This finding also provides new guidance for clinical treatment. In this study, the researchers used PI3K-targeted drugs for PI3K3CA mutants and estrogen receptor-positive breast cancer patients, using advanced tests and computer tools to analyze these samples, and they successfully found Activates the epigenetic regulatory protein KMT2D of the estrogen receptor. This finding makes KMT2D a core protein that directly links the two pathways, and also demonstrates the important role of epigenetic regulation in the pathogenesis of breast cancer. Shanghai Chuangsai Technology has excellent performance, interleukin cytokines, fetal bovine serum, electrophoresis equipment scientific instruments, raw material drug standards, chemical reagents, cell culture consumables, Shanghai Chuangsai, mass products special promotions, welcome to inquire! private label natural Hair care shampoo ,30 years experience guangzhou cosmetics factory supply ,OEM/ODM service is welcomed . Deep Cleansing Shampoo,Essential Oils Shampoo,Hair Loss Treatment Shampoo ,Shampoo for Dry Oily ,Anti-Dandruff Shampoo Athena(Guangzhou) Cosmetics Manufacturer Co., Ltd , https://www.gzathenaskincare.com
Guangzhou Athena Cosmetics Manufacturing Co.,Ltd is a subsidiary of YALAN international group which is located in Guangzhou,china.it is the production center of YALAN international group branding products,specialized in the development and production if cosmetics.ATHENA is qualified for import and export.
controls the quality in full accordance with GMP, ISO9001 quality system good manufacturing practice for cosmetics and key points of cosmetic production licence inspection.